Jefferies Group LLC reissued their buy rating on shares of AveXis, Inc. (NASDAQ:AVXS) in a report published on Friday. Jefferies Group LLC currently has a $108.00 price objective on the stock, up from their previous price objective of $92.00.

AVXS has been the subject of several other research reports. Sanford C. Bernstein assumed coverage on shares of AveXis in a research note on Thursday, July 27th. They issued an outperform rating and a $108.00 price objective for the company. Morgan Stanley assumed coverage on shares of AveXis in a research note on Thursday, August 3rd. They issued an overweight rating and a $118.00 price objective for the company. Chardan Capital set a $103.00 price objective on shares of AveXis and gave the company a buy rating in a research note on Sunday, June 18th. Citigroup Inc. set a $100.00 price target on shares of AveXis and gave the company a buy rating in a research report on Thursday, June 15th. Finally, Zacks Investment Research upgraded shares of AveXis from a sell rating to a hold rating in a research report on Thursday, July 13th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus price target of $100.70.

Shares of AveXis (NASDAQ AVXS) traded down 2.37% during mid-day trading on Friday, hitting $89.49. 673,773 shares of the company were exchanged. AveXis has a 12-month low of $32.31 and a 12-month high of $97.77. The firm’s market capitalization is $2.48 billion. The company’s 50-day moving average price is $85.66 and its 200-day moving average price is $73.89.

AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.97) by $1.10. During the same quarter last year, the company earned ($0.68) EPS. Equities research analysts predict that AveXis will post ($4.36) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Jefferies Group LLC Reiterates “Buy” Rating for AveXis, Inc. (NASDAQ:AVXS)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/12/jefferies-group-llc-reiterates-buy-rating-for-avexis-inc-nasdaqavxs.html.

In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $70.91, for a total value of $126,219.80. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $126,219.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 5,340 shares of company stock valued at $434,872. Corporate insiders own 18.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of AveXis by 3,055.6% in the first quarter. BlackRock Inc. now owns 1,708,386 shares of the company’s stock valued at $129,888,000 after buying an additional 1,654,248 shares during the period. Alliancebernstein L.P. boosted its position in shares of AveXis by 4,448.8% in the second quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock valued at $46,418,000 after buying an additional 552,546 shares during the period. FMR LLC boosted its position in shares of AveXis by 13.1% in the second quarter. FMR LLC now owns 4,705,433 shares of the company’s stock valued at $386,598,000 after buying an additional 544,475 shares during the period. Vanguard Group Inc. boosted its stake in AveXis by 31.8% in the second quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after buying an additional 380,396 shares during the period. Finally, Marshall Wace North America L.P. boosted its stake in AveXis by 813.3% in the second quarter. Marshall Wace North America L.P. now owns 303,084 shares of the company’s stock valued at $24,853,000 after buying an additional 269,900 shares during the period. Hedge funds and other institutional investors own 90.68% of the company’s stock.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Stock Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related stocks with our FREE daily email newsletter.